Status:
COMPLETED
Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Ovarian Cancer
Fallopian Tube Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE3
Brief Summary
The objective of this study is to assess the safety and efficacy of patupilone compared to pegylated liposomal doxorubicin. Additionally, this study will assess the ability of patupilone to extend the...
Eligibility Criteria
Inclusion
- 18 years of age or older
- Confirmed diagnosis of ovarian, fallopian or peritoneal cancer
- No more than three chemotherapy regimens
- Most recent regimen must have been platinum based
Exclusion
- Have an unresolved bowel obstruction
- Have had previous chemotherapy within 3 weeks
- Recovering from any surgery for any cause
- Other protocol-defined inclusion/exclusion criteria will apply.
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
829 Patients enrolled
Trial Details
Trial ID
NCT00262990
Start Date
November 1 2005
Last Update
December 17 2020
Active Locations (149)
Enter a location and click search to find clinical trials sorted by distance.
1
Alaska Cancer Research & Education Center
Anchorage, Alaska, United States, 99508
2
Northern Arizona Hematology & Oncology Associates
Flagstaff, Arizona, United States, 86001
3
Mayo Center for Women's Health
Scottsdale, Arizona, United States, 85259
4
Northern Arizona Hematology & Oncology Associates
Sedona, Arizona, United States, 86336